Ovidiu has enjoyed over two decades as clinical and translational cardiovascular MD-PhD researcher, capitalizing on the expertise of talented multidisciplinary teams from both academia and pharmaceutical industry. His scientific interests include innovative diagnostics, treatments, and disease prevention strategies; he was a proud member of the Speedel Company that developed Aliskiren, the first in a class of medications known as direct renin inhibitors.